Form 4: Ionis Pharma CBO Sells Shares Under 10b5-1 Plan
Insider Transaction Report
Ionis Pharmaceuticals' Chief Business Officer, Joseph Baroldi, and his spouse sold company common stock totaling over $531,000 through pre-arranged trading plans.
Summary
- Joseph Baroldi, EVP, Chief Business Officer of Ionis Pharmaceuticals Inc., reported transactions involving the company's common stock.
- On March 3, 2026, Mr. Baroldi sold 4,096 shares of common stock at a price of $79.36 per share, totaling approximately $325,096.96.
- These shares were sold pursuant to a Rule 10b5-1 Trading Plan adopted by Mr. Baroldi on November 25, 2025.
- Mr. Baroldi's spouse also engaged in transactions on March 3 and March 4, 2026, under a separate Rule 10b5-1 Trading Plan adopted on November 25, 2025.
- The spouse exercised non-qualified stock options to acquire a total of 2,138 shares of common stock at exercise prices of $32.60 and $56.78 per share.
- Concurrently, the spouse sold a total of 2,563 shares of common stock at weighted average prices ranging from $80.00 to $81.01 per share, totaling approximately $205,935.43.
- Following these transactions, Mr. Baroldi directly beneficially owns 41,317 shares of common stock.
- Mr. Baroldi's spouse indirectly beneficially owns 4,347 shares of common stock and various non-qualified stock options.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a routine insider transaction under a pre-arranged plan, which typically carries a neutral sentiment as it is not necessarily indicative of management's view on future performance or a significant event for the company.
Future Outlook
This filing does not contain any forward-looking statements or guidance regarding the company's future outlook.
Industry Context
StockSavvy.ai notes that insider sales executed under Rule 10b5-1 trading plans are a common practice for corporate executives. These plans allow insiders to sell a predetermined number of shares at a predetermined time or price, helping them manage personal finances, diversify portfolios, and avoid accusations of trading on material non-public information. Such routine sales are generally not interpreted as a signal of management's negative outlook on the company's future performance.
Key Dates
| Date | Description |
|---|---|
| 01/04/2022 | Date exercisable for certain non-qualified stock options. |
| 01/03/2023 | Date exercisable for certain non-qualified stock options. |
| 11/25/2025 | Date Rule 10b5-1 Trading Plans were adopted by the reporting person and spouse. |
| 03/03/2026 | Transaction date for sales and option exercises by the reporting person and spouse. |
| 03/04/2026 | Transaction date for sales and option exercises by the spouse. |
| 03/05/2026 | Signature date of the Form 4 filing. |
| 01/03/2028 | Expiration date for certain non-qualified stock options. |
| 01/02/2032 | Expiration date for certain non-qualified stock options. |
Keywords
Ionis Pharmaceuticals, IONS, Insider Trading, Form 4, Stock Sale, Executive Compensation, Joseph Baroldi, 10b5-1 Plan
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.